Comparative Pharmacology
Head-to-head clinical analysis: LAMOTRIGINE versus TEGRETOL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMOTRIGINE versus TEGRETOL XR.
Lamotrigine vs TEGRETOL-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
Carbamazepine stabilizes inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
200-400 mg orally twice daily; maximum 1200 mg/day for monotherapy, 1600 mg/day for combination therapy.
None Documented
None Documented
Clinical Note
moderateLamotrigine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone propionate."
Clinical Note
moderateLamotrigine + Desmopressin
"The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin."
Clinical Note
moderateLamotrigine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Lamotrigine."
Clinical Note
moderateLamotrigine + Fluconazole
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Initial: 25-65 hours; chronic dosing: 12-17 hours due to autoinduction. Steady-state reached in 2-4 weeks.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Renal: ~72% as unchanged drug and metabolites (primarily glucuronides). Fecal: ~28% via bile (enterohepatic recirculation possible).
Category A/B
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Lamotrigine."